AbbVie stock moves down with RSI signaling oversold conditions near $204: weekly analysis

AbbVie (ABBV) stock has declined by 1.75% this week, trading below its 20- and 50-week moving averages, with momentum indicators suggesting oversold conditions and persistent bearish pressure. Despite a dividend hike and a new Humira discount, the stock is expected to remain range-bound between $194.11 and $203.66 next week, with a higher probability of further downside unless it reclaims its MA-50. Analysts warn of continued selling pressure and the critical importance of the $194.11 support level.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin